Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
For those wanting the home test kit, free rapid antigen tests will continue to be available through local public health units ...
EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
By mid-September, the Centers for Disease Control and Prevention reported the Omicron subvariant KP.3.1.1 accounted for most COVID-19 cases. KP.3.1.1 is a member of a group of variants nicknamed ...
The winter season ushers in a new globally spreading COVID-19 variant called XEC, a mix of KS.1.1 and KP.3.3, both from the ...
CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine
(RTTNews) - Pfizer (PFE) and BioNTech SE (BNTX) announced that the CHMP of the European Medicines Agency has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback